Share this bulletin
Get news bulletins by email

Bulletin The resurgent U.S. IPO market may already be showing signs of fatigue »

Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

Precision Biosciences Inc.

NAS: DTIL

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Precision Biosciences Inc.

Market open

DTIL

/zigman2/quotes/205502826/composite

0.37

Change

-0.01 -2.73%

Volume

Volume 314,448

Sep 25, 2023, 1:13 p.m.

Real time quotes

/zigman2/quotes/205502826/composite

Previous close

$ 0.38

$ 0.37

Change

-0.01 -2.73%

Day low

Day high

$0.35

$0.39

Open: 0.38

52 week low

52 week high

$0.35

$1.70

Market cap

$43.77M

Average volume

1.15M

P/E ratio

N/A

Rev. per Employee

$235,000

EPS

-0.80

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/dtil

MarketWatch News on DTIL

Precision Biosciences downgraded to market perform at BMO Capital

10:19 a.m. March 14, 2023

- Tomi Kilgore
Precision Biosciences started at outperform with $7 stock price target at BMO Capital

12:24 p.m. June 17, 2022

- Tomi Kilgore
Precision Biosciences stock price target cut to $16 vs. $24 at Stifel

7:06 a.m. March 16, 2022

- Ciara Linnane
Precision BioSciences stock rises on early-stage CAR-T trial data

9:42 a.m. Dec. 9, 2019

- Jaimy Lee
Big IPOs, Like Beyond Meat, Have Had a Good Year. WeWork Wants In.

11:44 a.m. Aug. 17, 2019

- Barron's Online
WeWork Wants in on the IPO Bonanza

12:35 p.m. Aug. 14, 2019

- Barron's Online
Precision Biosciences started at overweight with $23 stock price target at J.P. Morgan

7:56 a.m. April 22, 2019

- Tomi Kilgore
A Fidelity-Affiliated VC Fund Has Made Millions from This Biotech Stock IPO

1:55 p.m. April 4, 2019

- Barron's Online

/news/nonmarketwatch/company/us/dtil

Other News on DTIL

10-K: PRECISION BIOSCIENCES INC

8:21 a.m. March 9, 2023

- Edgar Online - (EDG = 10Q, 10K)
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

9:25 a.m. Nov. 8, 2022

- Zacks.com
10-Q: PRECISION BIOSCIENCES INC

8:09 a.m. Nov. 8, 2022

- Edgar Online - (EDG = 10Q, 10K)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates

9:15 a.m. Nov. 1, 2022

- Zacks.com
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos

12:38 p.m. Oct. 19, 2022

- Zacks.com
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

10:57 a.m. Aug. 10, 2022

- Zacks.com
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

10:32 a.m. Aug. 10, 2022

- Zacks.com
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

11:06 a.m. Aug. 9, 2022

- Zacks.com
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

11:02 a.m. Aug. 9, 2022

- Zacks.com
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

8:25 a.m. Aug. 8, 2022

- Zacks.com
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues

8:56 a.m. Aug. 5, 2022

- Zacks.com
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

12:39 p.m. Aug. 4, 2022

- Zacks.com
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates

12:30 p.m. Aug. 4, 2022

- Zacks.com
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates

12:26 p.m. Aug. 4, 2022

- Zacks.com

/news/pressrelease/company/us/dtil

Press Releases on DTIL

Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting

7:00 a.m. May 19, 2023

- BusinessWire - BZX
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting

5:07 p.m. May 12, 2023

- BusinessWire - BZX
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

7:00 a.m. May 9, 2023

- BusinessWire - BZX
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

5:07 p.m. May 8, 2023

- BusinessWire - BZX
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

7:00 a.m. May 2, 2023

- BusinessWire - BZX
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

8:00 a.m. April 20, 2023

- BusinessWire - BZX
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

4:22 p.m. April 19, 2023

- BusinessWire - BZX
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

8:00 a.m. April 18, 2023

- BusinessWire - BZX
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

7:00 a.m. April 13, 2023

- BusinessWire - BZX
Precision BioSciences to Participate in UpcomingGuggenheim Healthcare Talks Conference

7:00 a.m. March 27, 2023

- BusinessWire - BZX
European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

8:00 a.m. March 22, 2023

- BusinessWire - BZX
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

8:00 a.m. March 9, 2023

- BusinessWire - BZX
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023

8:00 a.m. March 2, 2023

- BusinessWire - BZX
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

8:00 a.m. Feb. 24, 2023

- BusinessWire - BZX
Precision BioSciences to Participate in UpcomingH.C. Wainwright Cell Therapy Virtual Conference

8:00 a.m. Feb. 22, 2023

- BusinessWire - BZX
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

8:00 a.m. Feb. 14, 2023

- BusinessWire - BZX
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

8:30 a.m. Jan. 9, 2023

- BusinessWire - BZX
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

8:00 a.m. Jan. 6, 2023

- BusinessWire - BZX
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

11:00 a.m. Dec. 10, 2022

- BusinessWire - BZX
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases

9:06 a.m. Nov. 30, 2022

- BusinessWire - BZX
Loading more headlines...

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Precision Biosciences Inc.

MarketWatch News on DTIL

Other News on DTIL

Press Releases on DTIL

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk